Hidradenitis suppurativa – es gibt Neues

Hidradenitis suppurativa (HS) ist eine chronisch-entzündliche Hauterkrankung, die oft eine enorme Belastung der Betroffenen und Behandler verursacht. Doch die Therapiemöglichkeiten haben sich in den letzten Jahren drastisch verbessert und reichen von neuen zielgerichteten Therapien über ergänzende Ansätze in der Ernährung bis hin zu chirurgischen Optionen. Haben die frustranen Therapieversuche ein Ende?

• Literatur

• 1 Kirsten N, Zander N, Augustin M. Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population. Arch Dermatol Res 2021; 313: 95-99
• 2 Wolk K, Join-Lambert O, Sabat R. Aetiology and pathogenesis of hidradenitis suppurativa. Br J Dermatol 2020; 183: 999-1010
• 3 Chu YL, Yu S. Hidradenitis suppurativa: an understanding of genetic factors and treatment. Biomedicines 2024; 12: 338
• 4 Abu Rached N, Gambichler T, Dietrich JW. et al. The role of hormones in hidradenitis suppurativa: a systematic review. Int J Mol Sci 2022; 23: 15250
• 5 Montero-Vilchez T, Diaz-Calvillo P, Rodriguez-Pozo C. et al. The burden of hidradenitis suppurativa signs and symptoms in quality of life: systematic review and meta-analysis. Int J Environ Res Public Health 2021; 18: 6709
• 6 Mintoff D, Benhadou F, Pace NP. et al. Metabolic syndrome and hidradenitis suppurativa: epidemiological, molecular, and therapeutic aspects. Int J Dermatol 2022; 61: 1175-1186
• 7 Singal A, Choudhry HS, Desai AD. et al. Hidradenitis suppurativa and polycystic ovary syndrome: analysis of demographics in the inpatient setting. Arch Dermatol Res 2023; 316: 4
• 8 Reka P, Janka EA, Soltesz L. et al. Chronisch inflammatory intestinal disorders in hidradenitis suppurativa. Dermatology 2023; 239: 592-600
• 9 Ovadja ZN, Schuit MM, van der Horst C. et al. Inter- and intrarater reliability of hurley staging for hidradenitis suppurativa. Br J Dermatol 2019; 181: 344-349
• 10 Zouboulis CC, Prens EP, Sayed CJ. et al. International hidradenitis suppurativa severity scoring system (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with hurley staging: a post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab. J Eur Acad Dermatol Venereol 2024; 38: e496-e499
• 11 Otten M, Augustin M, Blome C. et al. Measuring quality of life in hidradenitis suppurativa: development and validation of a disease-specific patient-reported outcome measure for practice and research. Acta Derm Venereol 2023; 103: adv00859
• 12 Zouboulis CC, Bechara FG, Fritz K. et al. S2k guideline for the treatment of hidradenitis suppurativa/acne inversa – short version. J Dtsch Dermatol Ges 2024; 22: 868-889
• 13 Kimball AB, Jemec GBE, Sayed CJ. et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet 2024; 403: 2504-2519
• 14 Orenstein LAV, Nguyen TV, Damiani G. et al. Medical and surgical management of hidradenitis suppurativa: a review of international treatment guidelines and implementation in general dermatology practice. Dermatology 2020; 236: 393-412
• 15 Lorite-Fuentes I, Montero-Vilchez T, Arias-Santiago S. et al. Potential benefits of the mediterranean diet and physical activity in patients with hidradenitis suppurativa: a cross-sectional study in a spanish population. Nutrients 2022; 14: 551
• 16 Aguwa C, Enwereji N, Santiago S. et al. Targeting dysbiosis in psoriasis, atopic dermatitis, and hidradenitis suppurativa: the gutskin axis and microbiome-directed therapy. Clin Dermatol 2023; 41: 640-649
• 17 Madaan T, Doan K, Hartman A. et al. Advances in microbiome-based therapeutics for dermatological disorders: current insights. Exp Dermatol 2024; 33: e70019